Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.

The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.

But with Brukinsa and degraders looming, will fixed dosing make the difference?

Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.

Enzomenib might be the most promising agent so far, on a cross-trial basis.

The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.